April show­ers bring more biotechs to Nas­daq, as Rain and Im­pel bump 2021's to­tal raise above $6B

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

What’s that in the sky — is it a bird? Is it a plane? No, it’s an­oth­er hand­ful of biotech IPOs.

Two more biotechs priced their pub­lic of­fer­ings late Thurs­day, com­ing just one day af­ter Zymer­gen blew folks away with its $500 mil­lion pric­ing. This week’s win­ners are Rain Ther­a­peu­tics and Im­pel Neu­rophar­ma, who raised $125 mil­lion and $80 mil­lion, re­spec­tive­ly. Rain priced at $17 and Im­pel’s shares de­buted at $15 apiece.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER